SEC Tracker
Get the app

Lite Strategy LITS

Lite Strategy Q2 FY25: net loss $30.8M; diluted EPS −$0.82

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Lite Strategy reported for Q2 FY25, the quarter ended Dec 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$30.8MAgainst −$2.7M in Q2 FY2510-Q income statement, on EDGAR
  2. Diluted EPS−$0.82Against −$0.40 in Q2 FY2510-Q income statement, on EDGAR
  3. Cash and cash equivalents$8.8M−63% from $23.7M in Q2 FY2510-Q balance sheet, on EDGAR
  4. Cash from operations−$1.9MAgainst −$3.7M in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Lite Strategy files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Actinium Pharmaceuticals ATNM public float $44M, Jun 30, 2025
  2. Fortress Biotech FBIO public float $44M, Jun 30, 2025
  3. Actuate Therapeutics ACTU public float $42M, Jun 30, 2025
  4. Acumen Pharmaceuticals ABOS public float $45M, Jun 30, 2025
  5. Opus Genetics IRD public float $46M, Jun 30, 2025